Latest News and Press Releases

Want to stay updated on the latest news?

Sign into Reader Account Create Reader Account

May 10, 2019 06:30 ET | Source: Stemline Therapeutics, Inc.

Stemline Therapeutics Reports First Quarter 2019 Financial Results

Net revenue for ELZONRIS was $5.05 million for the first quarterConference call and live webcast scheduled for today at 8:00 AM ET NEW YORK, May 10, 2019 (GLOBE NEWSWIRE) -- Stemline Therapeutics,...
May 08, 2019 07:00 ET | Source: Stemline Therapeutics, Inc.

Stemline Therapeutics to Host Conference Call on First Quarter 2019 Financial Results on May 10, 2019

NEW YORK, May 08, 2019 (GLOBE NEWSWIRE) -- Stemline Therapeutics, Inc. (Nasdaq: STML), a commercial-stage biopharmaceutical company focused on the development and commercialization of novel oncology...
April 25, 2019 07:00 ET | Source: Stemline Therapeutics, Inc.

Stemline Therapeutics Announces New England Journal of Medicine Publication of ELZONRIS (tagraxofusp) Pivotal Study Results

NEW YORK, April 25, 2019 (GLOBE NEWSWIRE) -- Stemline Therapeutics, Inc. (Nasdaq: STML), a commercial-stage biopharmaceutical company focused on the development and commercialization of novel...
March 18, 2019 07:00 ET | Source: Stemline Therapeutics, Inc.

Stemline Therapeutics to Participate in Panel on Myeloid Tumors at the 31st Annual ROTH Conference

NEW YORK, March 18, 2019 (GLOBE NEWSWIRE) -- Stemline Therapeutics, Inc. (Nasdaq: STML), a commercial-stage biopharmaceutical company focused on the development and commercialization of novel...
March 15, 2019 16:01 ET | Source: Stemline Therapeutics, Inc.

Stemline Therapeutics Reports Fourth Quarter 2018 Financial Results

NEW YORK, March 15, 2019 (GLOBE NEWSWIRE) -- Stemline Therapeutics, Inc. (Nasdaq: STML), a commercial-stage biopharmaceutical company focused on the development and commercialization of novel...
March 11, 2019 07:00 ET | Source: Stemline Therapeutics, Inc.

Stemline In-Licenses Worldwide Rights to Novel Selective RET Inhibitor (SL-1001); Expands Oncology Pipeline

NEW YORK, March 11, 2019 (GLOBE NEWSWIRE) -- Stemline Therapeutics, Inc. (Nasdaq: STML), a commercial-stage biopharmaceutical company focused on the development and commercialization of novel...
March 06, 2019 07:30 ET | Source: Stemline Therapeutics, Inc.

Stemline Therapeutics to Present at the Cowen and Company 39th Annual Health Care Conference

NEW YORK, March 06, 2019 (GLOBE NEWSWIRE) -- Stemline Therapeutics, Inc. (Nasdaq: STML), a commercial-stage biopharmaceutical company focused on the development and commercialization of novel...
January 30, 2019 07:30 ET | Source: Stemline Therapeutics, Inc.

Stemline Therapeutics Announces Validation of Marketing Authorization Application (MAA) by the European Medicines Agency (EMA)

NEW YORK, Jan. 30, 2019 (GLOBE NEWSWIRE) -- Stemline Therapeutics, Inc. (Nasdaq: STML), a commercial-stage biopharmaceutical company focused on the development and commercialization of novel...
January 18, 2019 11:21 ET | Source: Stemline Therapeutics, Inc.

Stemline Therapeutics Closes $92 Million Public Offering of Common Stock

NEW YORK, Jan. 18, 2019 (GLOBE NEWSWIRE) -- Stemline Therapeutics, Inc. (Nasdaq: STML), a commercial-stage biopharmaceutical company focused on discovering, acquiring, developing and commercializing...
January 15, 2019 22:04 ET | Source: Stemline Therapeutics, Inc.

Stemline Therapeutics Announces Upsizing and Pricing of $80 Million Public Offering of Common Stock

NEW YORK, Jan. 15, 2019 (GLOBE NEWSWIRE) -- Stemline Therapeutics, Inc. (Nasdaq: STML), a commercial-stage biopharmaceutical company focused on discovering, acquiring, developing and commercializing...